Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma

Clin Adv Hematol Oncol. 2005 Apr;3(4):297-9; discussion 300-2.
No abstract available

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary*
  • Bone Neoplasms / surgery
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Femoral Neoplasms / drug therapy
  • Femoral Neoplasms / surgery
  • Gemcitabine
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / secondary
  • Humans
  • Ifosfamide / administration & dosage
  • Irinotecan
  • Leucovorin / therapeutic use
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary*
  • Lung Neoplasms / surgery
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoadjuvant Therapy
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / radiotherapy
  • Osteosarcoma / secondary*
  • Palliative Care
  • Salvage Therapy
  • Scalp
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / secondary
  • Thoracotomy

Substances

  • Deoxycytidine
  • Etoposide
  • Irinotecan
  • Doxorubicin
  • Cisplatin
  • Leucovorin
  • Ifosfamide
  • Camptothecin
  • Methotrexate
  • Gemcitabine